Lifecore Biomedical Inc (LFCR) financials
Lifecore Biomedical revenue and earnings by year
Lifecore Biomedical's revenue was $129 million in the fiscal year to May 25, 2025, up 0.5% from the year before. Net income was -$38.7 million, -30.0% of revenue. Since the fiscal year to May 29, 2016, revenue has shrunk 13.5% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 | May 2020 | May 2019 | May 2018 | May 2017 | May 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 129 | 128 | 103 | 111 | 101 | 160 | 558 | 524 | 470 | 477 |
| Revenue growth | 0.5% | 24.2% | -7.2% | 10.3% | -37.0% | -71.3% | 6.4% | 11.6% | -1.5% | — |
| Gross profit | 40 | 42 | 28 | 39 | 39 | 39 | 81 | 78 | 79 | 67 |
| Gross margin | 31.3% | 32.6% | 27.1% | 35.1% | 38.6% | 24.6% | 14.5% | 14.9% | 16.9% | 14.0% |
| Operating income | -17 | -9 | -22 | -12 | -9 | -26 | 5 | 14 | 15 | -21 |
| Operating margin | -13.4% | -6.9% | -21.1% | -10.6% | -8.7% | -16.2% | 1.0% | 2.6% | 3.1% | -4.3% |
| Net income | -39 | 12 | -100 | -117 | -32 | -38 | 0 | 25 | 11 | -12 |
| Net margin | -30.0% | 9.4% | -96.4% | -104.9% | -32.0% | -23.9% | 0.1% | 4.7% | 2.3% | -2.4% |
| Diluted EPS | -$1.26 | $0.33 | -$3.32 | -$3.97 | -$1.10 | -$1.31 | $0.01 | $0.89 | $0.39 | -$0.43 |
| Free cash flow | -7 | -18 | -39 | -51 | 4 | -41 | -28 | -14 | 7 | -19 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open LFCR in Markets.
How Lifecore Biomedical makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| HA Manufacturing | $18.6M | 54.5% |
| Contract Development & Manufacturing Organization | $15.6M | 45.5% |
See also: LFCR valuation and P/E history · LFCR returns
No forecast, no recommendation. This page describes Lifecore Biomedical Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.